EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Eperzan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification [1] issued on	Commission Decision issued [2] / amended on	Product Information affected [3]	Summary
PSUSA/10175 /201703	Periodic Safety Update EU Single assessment - albiglutide	28/09/2017	n/a		PRAC Recommendation - maintenance
II/0031	Update of section 4.8 of the SmPC in order to include angioedema under the description of “Allergic reactions”. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder took the opportunity to implement minor editorial	14/09/2017		SmPC and PL	Signs of severe allergic reactions include raised and itchy rashes and swelling (sometimes of the face, mouth or throat, causing difficulty in breathing). Patients should seek medical help immediately if they observe these symptoms and stop taking Eperzan.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

	amendments throughout the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
II/0033	Update of the Package Leaflet in order to amend the layout and content of the Instructions for Use (IFU). In addition, the RMP version 8 has also been submitted to implement additional pharmacovigilance and risk minimisation activities addressing the safety concern of “medication errors/device issue potentially leading to lack of efficacy or inadequate diabetes control” C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	01/09/2017		PL	The Instructions for Use (IFU) were re-designed to address the issue of non-compliance with the instructions, which constitutes the largest proportion of medication errors. Results of the revised IFU user testing demonstrated that patients could administer Eperzan successfully and the error/unsuccessful administration rate was very low.
IAIN/0037	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	10/08/2017		SmPC and PL	
IA/0035	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	14/07/2017		SmPC	
II/0032	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	05/05/2017	n/a		
PSUSA/10175 /201609	Periodic Safety Update EU Single assessment - albiglutide	06/04/2017	n/a		PRAC Recommendation - maintenance

II/0028/G	This was an application for a group of variations. II: C.I.11.b - Submission of a revised RMP in order to introduce medication errors as a new important potential risk II: C.I.11.b – Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity - Study 204879: A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects with Type 2 Diabetes Mellitus II: C.I.11.b - Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity – Study 201840 - An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide with Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers II: C.I.11.b – Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity – Cross-sectional survey to assess the effectiveness of the proposed additional educational materials using Patient Connect C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	23/02/2017	n/a		

	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
II/0027/G	This was an application for a group of variations. Submission of the final study reports for non-clinical toxicity studies: 2015N232567 - Investigation of blood brain barrier penetration of albiglutide in mice and 2016N269355 - Subcutaneous juvenile toxicity study in mice. In addition, the MAH submitted a literature review on glucagon like peptide 1 receptor (GLP-1R) distribution patterns in thyroid and pancreas tissue and results of two additional juvenile toxicology dose response studies as part of this group of	15/12/2016	n/a		

	variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority				
PSUSA/10175 /201603	Periodic Safety Update EU Single assessment - albiglutide	13/10/2016	08/12/2016	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10175/201603.
IB/0026	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	31/08/2016	n/a		
II/0022	Update of section 6.6 of the SmPC for increased clarity in order to address the newly identified potential risk of medication errors. The Package Leaflet (including Instructions for Use) is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to combine SmPCs of authorised strengths and bring the Annex II and Annex IIIA in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	21/07/2016	08/12/2016	SmPC, Annex II, Labelling and PL	Patient should read the full Instructions for Use (IFU) including the Questions and Answers before starting the therapy and refer back to the IFU each time before injecting the dose.

IB/0025	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	20/06/2016	n/a		
II/0023/G	This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the	26/05/2016	n/a		

	obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation				
II/0020	B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	19/05/2016	n/a		
II/0019	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	28/04/2016	n/a		
PSUSA/10175 /201509	Periodic Safety Update EU Single assessment - albiglutide	14/04/2016	n/a		PRAC Recommendation - maintenance
IB/0021	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	31/03/2016	08/12/2016	SmPC and PL	
IB/0016	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	10/12/2015	n/a		

	Replacement/addition of a site where batch control/testing takes place				
N/0018	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/12/2015	08/12/2016	PL	
IA/0015	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	02/12/2015	n/a		
PSUSA/10175 /201503	Periodic Safety Update EU Single assessment - albiglutide	08/10/2015	n/a		PRAC Recommendation - maintenance
II/0013/G	This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	24/09/2015	n/a		
II/0012	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	09/07/2015	n/a		
PSUSA/10175 /201409	Periodic Safety Update EU Single assessment - albiglutide	10/04/2015	n/a		PRAC Recommendation - maintenance
IB/0011	To extend the albiglutide active substance shelf life from 24 months to 36 months at the currently registered storage condition "Store at ≤ -35°C,	23/12/2014	n/a		

	protected from light." B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
II/0008	Update of sections 4.8 of the Summary of Product Characteristics (SmPC) with information on hypersensitivity and allergic reactions. The Package Leaflet (PL) is updated accordingly. In addition, minor editorial changes are made to sections 5.1 and 6.6 of the SmPC, the Annex IIIA and the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	18/12/2014	19/06/2015	SmPC, Labelling and PL	The MAH conducted an updated review of data from 7 clinical trials included in the safety analysis of the initial marketing authorisation using a MedDRA SMQ version 16.1 for hypersensitivity reactions. The overall incidence of any serious hypersensitivity reaction identified with this query was similar in the albiglutide group compared to the all comparators group (0.4%). Furthermore, the overall incidence of any event of hypersensitivity reactions also appeared to be similar between the groups; 17.1% vs. 14.9% for albiglutide vs. the all comparators group However, a non-serious hypersensitivity event was consistent with a possible drug-related systemic hypersensitivity reaction. Consequently, section 4.8 of the SmPC was updated to indicate that possible hypersensitivity reactions (e.g. pruritus, erythema), including a case with generalized pruritus and rash with dyspnoea, have been reported in clinical trials with albiglutide.
II/0006	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	25/09/2014	n/a		
II/0005	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance	25/09/2014	n/a		

	which may have a significant impact on the medicinal product and is not related to a protocol				
IB/0004/G	This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	05/09/2014	19/06/2015	SmPC, Labelling and PL	
IB/0007	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	13/08/2014	n/a		
IG/0442	A.1 - Administrative change - Change in the name and/or address of the MAH	05/06/2014	19/06/2015	SmPC, Labelling and PL	
IB/0001	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	09/05/2014	n/a		
IB/0002	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	02/05/2014	n/a		